Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BECTON DICKINSON & COBDX · Entity 2498 | EVP and Pres, Life Sciences | November 26, 2021 | November 30, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BECTON DICKINSON & CO
Report date November 26, 2021 · Filed November 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,662 |
Ending reported balance
After 2021-11-26 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-11-26 · Grant · Acquired 1,686 · Balance 10,344 F1: Represents shares vesting under performance units granted on November 26, 2018. Row 2 · 2021-11-26 · Tax withholding · Disposed 798 · Balance 9,546 F2: Represents shares withheld for payment of withholding taxes in connection with (A) vesting of the performance units referred to in footnote (1) and (B) the vesting of restricted stock units as previously reported on Table I. Row 3 · 2021-11-26 · Grant · Acquired 2,116 · Balance 11,662 F3: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $245.09 · Expires 2031-11-26 | Direct | 15,121 |
Reported balance
After 2021-11-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-26 · Grant · Acquired 15,121 · Balance 15,121 F6: The stock appreciation rights vest in four annual installments beginning November 26, 2022. |
| Common StockSEC Table I · non-derivative | IndirectGSIP Trust | 2,554 |
Reported balance
Holding disclosure · report date 2021-11-26 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,554 F4: Represents shares of common stock held under the Becton, Dickinson and Company Global Share Investment Program (the "GSIP"). The information presented for the GSIP is as of May 31, 2019. |
| Common StockSEC Table I · non-derivative | IndirectSIP Trust | 1,108 |
Reported balance
Holding disclosure · report date 2021-11-26 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,108 F5: Represents shares of common stock held under the Becton, Dickinson and Company Savings Incentive Plan (the "SIP"). The information presented for the SIP is as of May 31, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares vesting under performance units granted on November 26, 2018.
F2: Represents shares withheld for payment of withholding taxes in connection with (A) vesting of the performance units referred to in footnote (1) and (B) the vesting of restricted stock units as previously reported on Table I.
F3: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.
F4: Represents shares of common stock held under the Becton, Dickinson and Company Global Share Investment Program (the "GSIP"). The information presented for the GSIP is as of May 31, 2019.
F5: Represents shares of common stock held under the Becton, Dickinson and Company Savings Incentive Plan (the "SIP"). The information presented for the SIP is as of May 31, 2021.
F6: The stock appreciation rights vest in four annual installments beginning November 26, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 26, 2021 Filed Nov 30, 2021 17:49 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantStock Appreciation Rights · Derivative | 15,121 | $0.00 Strike: $245.09 | $0.00 |
DisclosureSEC source: 0001543407-21-000055 · edgar.xml · derivative · entry 6 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,121 Underlying: Common Stock · 15,121 shares Expires 2031-11-26 F6 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 26, 2022. Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 17:49 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 2,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-21-000055 · edgar.xml · nonDerivative · entry 3 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,662 F3 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 17:49 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Tax withholdingCommon Stock | 798 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-21-000055 · edgar.xml · nonDerivative · entry 2 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,546 F2 · shares: Represents shares withheld for payment of withholding taxes in connection with (A) vesting of the performance units referred to in footnote (1) and (B) the vesting of restricted stock units as previously reported on Table I. Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 17:49 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 1,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-21-000055 · edgar.xml · nonDerivative · entry 1 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,344 F1 · shares: Represents shares vesting under performance units granted on November 26, 2018. Read SEC document |
| November 26, 2020 Filed Nov 30, 2020 21:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantStock Appreciation Rights · Derivative | 5,893 | $0.00 Strike: $227.47 | $0.00 |
DisclosureSEC source: 0001543407-20-000053 · edgar.xml · derivative · entry 6 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,893 Underlying: Common Stock · 5,893 shares Expires 2030-11-26 F6 · derivative.exercise_date: The stock appreciation rights vest in three annual installments beginning November 26, 2021. Read SEC document |
| November 26, 2020 Filed Nov 30, 2020 21:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantStock Appreciation Rights · Derivative | 21,694 | $0.00 Strike: $227.47 | $0.00 |
DisclosureSEC source: 0001543407-20-000053 · edgar.xml · derivative · entry 5 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,694 Underlying: Common Stock · 21,694 shares Expires 2030-11-26 F5 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 26, 2021. Read SEC document |
| November 26, 2020 Filed Nov 30, 2020 21:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Tax withholdingCommon Stock | 672 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-20-000053 · edgar.xml · nonDerivative · entry 2 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,658 F2 · shares: Represents shares withheld for payment of withholding taxes in connection with (A) vesting of the performance units referred to in footnote (1) and (B) the vesting of restricted stock units as previously reported on Table I. Read SEC document |
| November 26, 2020 Filed Nov 30, 2020 21:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 949 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-20-000053 · edgar.xml · nonDerivative · entry 1 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,330 F1 · shares: Represents shares vesting under performance units granted on November 26, 2017. Read SEC document |
| February 04, 2020 Filed Feb 5, 2020 14:13 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 1,430 | $285.00 | $407,550.00 |
DisclosureSEC source: 0001543407-20-000022 · edgar.xml · nonDerivative · entry 1 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,381 Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 14:45 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionStock Appreciation Rights · Derivative | 12,153 | $0.00 Strike: $134.73 | $0.00 |
DisclosureSEC source: 0001543407-19-000076 · edgar.xml · derivative · entry 6 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,153 shares Expires 2024-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 25, 2015. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 14:45 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 11,860 | $269.51 | $3,196,388.60 |
DisclosureSEC source: 0001543407-19-000076 · edgar.xml · nonDerivative · entry 3 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,811 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $268.46 through $270.03. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Certain of the reported transactions were made pursuant to a 10b5-1 plan entered into on December 4, 2018. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 14:45 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Disposition to issuerCommon Stock | 6,068 | $269.51 | $1,635,386.68 |
DisclosureSEC source: 0001543407-19-000076 · edgar.xml · nonDerivative · entry 2 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,671 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $268.46 through $270.03. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Certain of the reported transactions were made pursuant to a 10b5-1 plan entered into on December 4, 2018. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 14:45 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionCommon Stock | 12,153 | $134.73 | $1,637,373.69 |
DisclosureSEC source: 0001543407-19-000076 · edgar.xml · nonDerivative · entry 1 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $268.46 through $270.03. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Certain of the reported transactions were made pursuant to a 10b5-1 plan entered into on December 4, 2018. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 18:41 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantStock Appreciation Rights · Derivative | 19,361 | $0.00 Strike: $255.22 | $0.00 |
DisclosureSEC source: 0001543407-19-000058 · edgar.xml · derivative · entry 5 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,361 Underlying: Common Stock · 19,361 shares Expires 2029-11-26 F5 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 26, 2020. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 18:41 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Tax withholdingCommon Stock | 1,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-19-000058 · edgar.xml · nonDerivative · entry 2 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,586 F2 · shares: Represents shares withheld for payment of withholding taxes in connection with (A) vesting of the performance units referred to in footnote (1) and (B) the vesting of restricted stock units as previously reported on Table I. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 18:41 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 1,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-19-000058 · edgar.xml · nonDerivative · entry 1 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,989 F1 · shares: Represents shares vesting under performance units granted on November 26, 2016. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 14:13 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionStock Appreciation Rights · Derivative | 3,483 | $0.00 Strike: $108.89 | $0.00 |
DisclosureSEC source: 0001543407-19-000026 · edgar.xml · derivative · entry 7 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,483 shares Expires 2023-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 26, 2014. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 14:13 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 109 | $255.00 | $27,795.00 |
DisclosureSEC source: 0001543407-19-000026 · edgar.xml · nonDerivative · entry 4 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,482 Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 14:13 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 1,995 | $255.00 | $508,725.00 |
DisclosureSEC source: 0001543407-19-000026 · edgar.xml · nonDerivative · entry 3 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,591 Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 14:13 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Disposition to issuerCommon Stock | 1,488 | $255.00 | $379,440.00 |
DisclosureSEC source: 0001543407-19-000026 · edgar.xml · nonDerivative · entry 2 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,586 Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 14:13 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionCommon Stock | 3,483 | $108.89 | $379,263.87 |
DisclosureSEC source: 0001543407-19-000026 · edgar.xml · nonDerivative · entry 1 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 20:05 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionStock Appreciation Rights · Derivative | 4,864 | $0.00 Strike: $108.89 | $0.00 |
DisclosureSEC source: 0001543407-19-000025 · edgar.xml · derivative · entry 7 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,483 Underlying: Common Stock · 4,864 shares Expires 2023-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 26, 2014. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 20:05 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 2,021 | $255.03 | $515,415.63 |
DisclosureSEC source: 0001543407-19-000025 · edgar.xml · nonDerivative · entry 4 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,591 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $255 through $255.75. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 20:05 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 2,787 | $255.03 | $710,768.61 |
DisclosureSEC source: 0001543407-19-000025 · edgar.xml · nonDerivative · entry 3 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,612 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $255 through $255.75. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 20:05 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Disposition to issuerCommon Stock | 2,077 | $255.03 | $529,697.31 |
DisclosureSEC source: 0001543407-19-000025 · edgar.xml · nonDerivative · entry 2 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,399 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $255 through $255.75. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 20:05 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionCommon Stock | 4,864 | $108.89 | $529,640.96 |
DisclosureSEC source: 0001543407-19-000025 · edgar.xml · nonDerivative · entry 1 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 20:48 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantStock Appreciation Rights · Derivative | 18,107 | $0.00 Strike: $242.10 | $0.00 |
DisclosureSEC source: 0001543407-18-000083 · edgar.xml · derivative · entry 6 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,107 Underlying: Common Stock · 18,107 shares Expires 2028-11-26 F6 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 26, 2019. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 20:48 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 1,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-18-000083 · edgar.xml · nonDerivative · entry 3 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,612 F3 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 20:48 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Tax withholdingCommon Stock | 1,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-18-000083 · edgar.xml · nonDerivative · entry 2 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,623 F2 · shares: Represents shares withheld for payment of withholding taxes in connection with (A) vesting of the performance units referred to in footnote (1) and (B) the vesting of restricted stock units as previously reported on Table I. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 20:48 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 2,445 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-18-000083 · edgar.xml · nonDerivative · entry 1 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,041 F1 · shares: Represents shares vesting under performance units granted on November 26, 2015. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 14:18 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 4,530 | $237.01 | $1,073,655.30 |
DisclosureSEC source: 0001543407-18-000070 · edgar.xml · nonDerivative · entry 1 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,596 Read SEC document |
| November 26, 2017 Filed Nov 28, 2017 14:00 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantStock Appreciation Rights · Derivative | 11,424 | $0.00 Strike: $226.28 | $0.00 |
DisclosureSEC source: 0001543407-17-000046 · edgar.xml · derivative · entry 6 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,424 Underlying: Common Stock · 11,424 shares Expires 2027-11-26 F6 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 26, 2018. Read SEC document |
| November 26, 2017 Filed Nov 28, 2017 14:00 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 1,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-17-000046 · edgar.xml · nonDerivative · entry 3 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,126 F3 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. Read SEC document |
| November 25, 2017 Filed Nov 28, 2017 14:00 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Tax withholdingCommon Stock | 2,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-17-000046 · edgar.xml · nonDerivative · entry 2 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,934 F2 · shares: Represents shares withheld for payment of withholding taxes in connection with (A) vesting of the performance units referred to in footnote (1) and (B) the vesting of restricted stock units as previously reported on Table I. Read SEC document |
| November 25, 2017 Filed Nov 28, 2017 14:00 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 2,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-17-000046 · edgar.xml · nonDerivative · entry 1 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,125 F1 · shares: Represents shares vesting under performance units granted on November 25, 2014. Read SEC document |
| August 14, 2017 Filed Aug 14, 2017 20:52 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionStock Appreciation Rights · Derivative | 12,003 | $0.00 Strike: $76.18 | $0.00 |
DisclosureSEC source: 0001543407-17-000029 · edgar.xml · derivative · entry 6 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,003 shares Expires 2022-11-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 20, 2013. Read SEC document |
| August 14, 2017 Filed Aug 14, 2017 20:52 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 7,463 | $201.41 | $1,503,122.83 |
DisclosureSEC source: 0001543407-17-000029 · edgar.xml · nonDerivative · entry 3 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,320 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $201.20 through $201.62. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| August 14, 2017 Filed Aug 14, 2017 20:52 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Disposition to issuerCommon Stock | 4,540 | $201.41 | $914,401.40 |
DisclosureSEC source: 0001543407-17-000029 · edgar.xml · nonDerivative · entry 2 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,783 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $201.20 through $201.62. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| August 14, 2017 Filed Aug 14, 2017 20:52 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Exercise / conversionCommon Stock | 12,003 | $76.18 | $914,388.54 |
DisclosureSEC source: 0001543407-17-000029 · edgar.xml · nonDerivative · entry 1 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2016 Filed Nov 29, 2016 17:04 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantStock Appreciation Rights · Derivative | 10,096 | $0.00 Strike: $170.69 | $0.00 |
DisclosureSEC source: 0001543407-16-000144 · edgar.xml · derivative · entry 6 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,096 Underlying: Common Stock · 10,096 shares Expires 2026-11-26 F6 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 26, 2017. Read SEC document |
| November 26, 2016 Filed Nov 29, 2016 17:04 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 1,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-16-000144 · edgar.xml · nonDerivative · entry 3 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,320 F3 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. Read SEC document |
| November 26, 2016 Filed Nov 29, 2016 17:04 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | Tax withholdingCommon Stock | 1,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-16-000144 · edgar.xml · nonDerivative · entry 2 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,290 F2 · shares: Represents shares withheld for payment of withholding taxes in connection with vesting of the performance units referred to in footnote (1) and the vesting of restricted stock units as previously reported on Table I. Read SEC document |
| November 26, 2016 Filed Nov 29, 2016 17:04 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 2,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-16-000144 · edgar.xml · nonDerivative · entry 1 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,816 F1 · shares: Represents shares vesting under performance units granted on November 26, 2013. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.